Benign Prostatic Hyperplasia And Sexual Dysfunction: Review Of The Impact Of New Medical And Surgical Therapies On Sexual Health
June 2025
in “
Current Urology Reports
”
TLDR New BPH treatments have low sexual dysfunction risk but may not improve urinary symptoms as much as traditional surgery.
Recent studies on treatments for benign prostatic hyperplasia (BPH) such as Optilume, Rezum, Urolift, iTind, and prostatic artery embolism show minimal risk of sexual dysfunction but offer less improvement in lower urinary tract symptoms (LUTS) compared to transurethral resection of the prostate (TURP) and simple prostatectomy. Aquablation provides similar LUTS improvement to TURP while reducing ejaculatory dysfunction. It is crucial to counsel patients on the sexual dysfunction risks of BPH treatments. Future research should focus on comparing minimally invasive surgical therapies and gathering long-term data on their effects on urinary and sexual function.
